SHARE IN FOCUS: Morphosys on the decline by numbers – multi-year low

Thursday, 11/11/2021 12:11 PM from


| Views: 13

Scientists at work in a medical laboratory (symbolic image). © SolStock / E + / Getty Images

FRANKFURT (dpa-AFX) – The shares of the biotechnology company Morphosys (MorphoSys share) have accelerated their most recent decline according to the figures presented the previous evening. In the morning, the price had temporarily slipped by almost eleven percent to 34.24 euros and reached its lowest level since 2016. The price has recently recovered somewhat, but was still six and a half percent in the red at 35.91 euros at noon.

Analyst Vineet Agrawal from Citigroup (Citigroup share) judged in a study on Thursday that the share continues to lack a timely price driver. For some time now, paper has been one of the big losers on the stock market. Since the multi-year high of 146.30 at the beginning of 2020, it has fallen by around 75 percent – no other German standard value has lost more in the period. The company is only worth around 1.2 billion euros on the stock exchange.


Further down?

Short-term position in MorphoSys

Ask: 0,90

Leverage: 5.74

with moderate leverage

HSBC Trinkaus & Burkhardt AG

The base prospectus as well as the final terms and the key information sheets are available here: TT86XG,. Also note the further notes to this advertisement. The issuer is entitled to terminate securities with an open-end term. You can find license information here.


Subscribe to more news about American Lithium shares for free

ARIVA.DE publishes analyzes, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that is recognizably posted by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Other users were also interested in this article:

Leave A Comment